Datroway Granted Priority Review in the US as 1st-Line Treatment for Patients With Metastatic Triple-Negative Breast Cancer Who are Not Candidates for Immunotherapy
February 04, 2026
February 04, 2026
WILMINGTON, Delaware, Feb. 4 -- AstraZeneca, a biopharmaceutical company, issued the following news release:
* * *
DATROWAY(R) (datopotamab deruxtecan-dlnk) granted Priority Review in the US as 1st-line treatment for patients with metastatic triple-negative breast cancer who are not candidates for immunotherapy
Based on results from TROPION-Breast02, showing AstraZeneca and Daiichi Sankyo's DATROWAY significantly improved overall survival vs. chemother . . .
* * *
DATROWAY(R) (datopotamab deruxtecan-dlnk) granted Priority Review in the US as 1st-line treatment for patients with metastatic triple-negative breast cancer who are not candidates for immunotherapy
Based on results from TROPION-Breast02, showing AstraZeneca and Daiichi Sankyo's DATROWAY significantly improved overall survival vs. chemother . . .